Form 4: Astera Labs Director Jack R. Lazar Sells Shares Under 10b5-1 Plan

Director Jack R. Lazar of Astera Labs sold a total of 12,500 shares of common stock on November 15, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Jack R. Lazar, a director at Astera Labs, sold 12,500 shares of common stock on November 15, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2024.
• The shares were sold in multiple transactions at varying prices, with weighted average prices reported for each set of transactions.
• The weighted average sale prices ranged from $85.7268 to $88.2906 per share.
• Following these transactions, Mr. Lazar directly owns 122,500 shares of Astera Labs common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine insider stock sale under a pre-arranged plan, which is neither positive nor negative in itself. It is a neutral event.

Risks

• Sales by insiders, even under pre-arranged plans, can sometimes be perceived negatively by the market.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives and directors to use 10b5-1 plans to manage their stock sales and avoid accusations of trading on inside information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among public company executives and directors to manage their stock sales.
• The reported prices are within the normal trading range for Astera Labs stock, indicating no unusual market activity.

Stakeholder Impact

• The stock sales may have a minor impact on the stock price, but the pre-arranged nature of the sales should mitigate any significant negative reaction.

Key Dates

Keywords

Astera Labs, insider trading, Form 4, Rule 10b5-1, stock sale, Jack R. Lazar, director